November 19, 2026
Health news, explained with evidence
LIVE
JAK Inhibitor Shows Potential in Managing Immune Dysregulation in Down Syndrome Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women Investigational Quadruple Receptor Agonist Shows Weight Loss Potential in Phase II Trial CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities JAK Inhibitor Shows Potential in Managing Immune Dysregulation in Down Syndrome Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women Investigational Quadruple Receptor Agonist Shows Weight Loss Potential in Phase II Trial CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities

JAK Inhibitor Shows Potential in Managing Immune Dysregulation in Down Syndrome

🔬 Research 2 min read 👁 0

A phase 2 clinical trial indicates that the medication tofacitinib can safely reduce chronic immune overactivity in individuals with Down syndrome, leading to improvements in inflammatory skin conditions.

JAK Inhibitor Shows Potential in Managing Immune Dysregulation in Down Syndrome🔬Research

Photo: Medical Xpress

Key points

  • Tofacitinib effectively reduced systemic inflammation and interferon activity in trial participants.
  • Patients showed marked improvement in chronic inflammatory skin conditions like hidradenitis suppurativa.
  • Preliminary neuropsychological data showed positive trends, but further controlled research is required to confirm cognitive benefits.

Researchers at the University of Colorado Anschutz's Linda Crnic Institute have conducted a phase 2 clinical trial investigating the use of tofacitinib, a JAK inhibitor, in adolescents and adults with Down syndrome. The study, published in Cell Reports Medicine, suggests that targeting the excessive interferon signaling caused by an extra copy of chromosome 21 can effectively lower systemic inflammation without compromising normal immune defenses.

Participants in the trial, who also suffered from inflammatory skin conditions such as hidradenitis suppurativa and alopecia areata, received the medication twice daily for 16 weeks. Results showed significant reductions in inflammatory markers and metabolites, including neurotoxic quinolinic acid. Furthermore, patients experienced clinical improvements in their skin conditions and reported better quality of life scores.

While the study also noted improvements in certain neuropsychological tests related to memory and attention, researchers caution that these findings are preliminary. Because the trial lacked a placebo control group, it is unclear if these cognitive changes were a direct result of the medication or other external factors. The study met its primary safety endpoints, though larger, long-term trials are necessary to fully establish the safety and efficacy of this treatment approach.

What to know: This study is an early-stage clinical trial. Patients should consult with their healthcare providers regarding any treatment decisions, as JAK inhibitors carry known risks that require careful medical monitoring.

Source Medical Xpress — medicalxpress.com/news/2026-11-immune-overactivity-syndrome-phase-clini… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.